01—Abstract
Summary
Summary of the 10-Q filed August 7, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated's Form 10-Q for the quarter ended June 30, 2025 shows product revenues, net of $107.4 milliona for the three months ended June 30, 2025, up from $90.3 million, and $200.2 million for the six months, up from $165.8 million.
The company reported a net loss of $321.7 millionb for the quarter ($1.70 per share) and $578.3 million for the six months ($3.12 per share). Operating expenses rose sharply, with SG&A of $154.8 million for the quarter and R&D of $177.2 million, the filing attributing the SG&A increase largely to commercial readiness activities for brensocatib. The balance sheet strengthened considerably during the period.
Cash and cash equivalents were $1,284.3 millionc at June 30, 2025, compared with $555.0 million at December 31, 2024, and marketable securities were $572.4 million. The increase was driven mainly by an underwritten offering in June 2025 of 8,984,375 shares at $96.00 per share, which provided estimated net proceeds of $823.1 million, and by the conversion and redemption of the 2028 Convertible Notes, which were settled in roughly 17.9 million shares. Debt, long-term fell to $538.5 million from $1,103.4 million.
Net cash used in operating activities was $467.7 milliond for the six months. The company states it has sufficient funds to meet its needs for at least the next 12 months.
Clinical and regulatory milestones described in the filing include the FDA's acceptance of the brensocatib NDA with priority review and a PDUFA target action date of August 12, 2025, positive topline Phase 2b results for TPIP in PAH announced in June 2025, and the first patient dosed in the INS1201 Phase 1 ASCEND trial in July 2025. The filing also notes that the ENCORE topline data for ARIKAYCE are anticipated in the first half of 2026.
02—Key points
Key Highlights
- Product revenues, net rose to $107.4 million for Q2 2025 from $90.3 million in Q2 2024, and to $200.2 million for the six months from $165.8 million, driven by ARIKAYCE sales in the US, Japan, and Europe and rest of world.
- Net loss widened to $321.7 million for Q2 2025 (EPS of $(1.70)) from $300.6 million in Q2 2024, and to $578.3 million for the six months (EPS of $(3.12)) from $457.7 million.
- SG&A expenses increased 45.2% to $154.8 million in Q2 2025, primarily from compensation and professional fees tied to commercial readiness for brensocatib; R&D expenses rose 20.7% to $177.2 million, mainly on higher manufacturing costs.
- Cash and cash equivalents reached $1,284.3 million at June 30, 2025, up from $555.0 million at year-end 2024, following net proceeds of $823.1 million from a June 2025 equity offering.
- Long-term debt declined to $538.5 million from $1,103.4 million after the 2028 Convertible Notes were converted and redeemed in the second quarter of 2025.
- Brensocatib NDA for bronchiectasis was accepted with priority review, with a PDUFA target action date of August 12, 2025; the filing anticipates a US launch in Q3 2025 if approved.
- Positive Phase 2b TPIP results in PAH were announced in June 2025, with a Phase 3 PAH trial planned for early 2026.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 7, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $107.42M$90.34M | +18.9% |
| Cost of Revenue | $28.07M$20.96M | +33.9% |
| Gross Profit | $79.34M$69.38M | +14.4% |
| R&D Expenses | $177.19M$146.75M | +20.7% |
| SG&A Expenses | $154.76M$106.57M | +45.2% |
| Operating Expenses | $420.29M$379.24M | +10.8% |
| Operating Income | -$312.88M-$288.90M | −8.3% |
| Interest Expense | $21.25M$21.27M | −0.1% |
| Net Income | -$321.69M-$300.61M | −7.0% |
| EPS (Basic) | $-1.70$-1.94 | +12.4% |
| EPS (Diluted) | $-1.70$-1.94 | +12.4% |
| Shares Outstanding (Basic) | 189.30M154.70M | +22.4% |
| Shares Outstanding (Diluted) | 189.30M154.70M | +22.4% |
05—Questions
Frequently Asked Questions
How much cash does Insmed have, and is it funded for the near term?
Insmed reported $1,284.3 million in cash and cash equivalents and $572.4 million in marketable securities as of June 30, 2025. The company states it currently has sufficient funds to meet its financial needs for at least the next 12 months, but it may raise additional capital in the future.
What drove the increase in product revenue?
Product revenues, net, consist of ARIKAYCE sales. Revenue for the three months ended June 30, 2025 increased $17.1 million, or 18.9%, with Japan up 45.3%, Europe and rest of world up 48.3%, and US up 7.7%, according to the filing's revenue table.
Why did operating expenses rise and what does the company expect going forward?
SG&A rose mainly on compensation, stock-based compensation, and professional fees tied to commercial readiness activities for brensocatib. R&D rose mainly on manufacturing costs. The company expects R&D and SG&A expenses to increase in 2025 relative to 2024.
What happened to the convertible notes and debt balance?
The 2028 Convertible Notes were converted into about 17.9 million common shares in the second quarter of 2025, and the remaining outstanding notes were redeemed on June 6, 2025 at 100% of principal plus accrued interest. Long-term debt fell to $538.5 million from $1,103.4 million at December 31, 2024.
What are the key upcoming catalysts disclosed in the filing?
The filing cites a brensocatib PDUFA target action date of August 12, 2025, with European and UK regulatory submissions accepted and a Japan submission planned for the second half of 2025. It also cites ARIKAYCE ENCORE topline data expected in the first half of 2026, brensocatib BiRCh topline data expected by the end of 2025, and a planned TPIP Phase 3 PAH start in early 2026.
06—Continue